Prices have dropped dramatically in some countries (primarily in some high-burden, low-and lower middle income countries), facilitated by the introduction of generic versions of these medicines.
9384
可供国家用于治疗丙型肝炎的直接作用抗病毒药物清单正在加长。
The list of DAAs available to countries for treating hepatitis C is growing.
9385
世卫组织刚刚对这些药物之一，即索非布韦的第一个非专利版本进行了资格预审。
WHO has just prequalified the first generic version of one of these drugs: sofosbuvir.
The average price of the required three-month treatment course of this generic is between US$260 and US$280, a small fraction of the original cost of the medicine when it first went on the market in 2013. WHO prequalification guarantees a product’s quality, safety and efficacy and means it can now be procured by the United Nations and financing agencies such as UNITAID, which now includes medicines for people living with HIV who also have hepatitis C in the portfolio of conditions it covers.
9387
乙型肝炎治疗
Hepatitis Btreatment
9388
由于慢性乙型肝炎病毒感染的全球发病率和死亡率高，对于其新疗法的开发也给予很大关注。
With high morbidity and mortality globally, there is great interest also in the development of new therapies for chronic hepatitis B virus infection.
The most effective current hepatitis B treatment, tenofovir, (which is not curative and which in most cases needs to be taken for life), is available for as low as $48 per year in many low and middle income countries.
9390
此外，还迫切需要扩大对乙型肝炎检测的获取。
There is also an urgent need to scale up access to hepatitis B testing.